Document is current
Any future updates will be listed below
-
Authors
Anno, Shohei
Sugioka, Yuko
Inui, Kentaro
Tada, Masahiro
Okano, Tadashi
Mamoto, Kenji
Koike, Tatsuya
- License Information
-
More Information
Article History
Received: 12 November 2017
Revised: 11 February 2018
Accepted: 1 March 2018
First Online: 10 March 2018
Compliance with ethical standards
: The Ethics Committee at the Osaka City University Medical School approved the study protocol (no. 1660, 2009). The study was carried out in compliance with the Declaration of Helsinki, and informed consent was obtained from all participants prior to enrolment.
: Tatsuya Koike has received research fees, consulting fees, or other remuneration from AbbVie, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Eli Lilly, Mitsubishi Tanabe Pharma Co., MSD K.K., Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical Co. Ltd., Teijin Pharma, and UCB. Kentaro Inui has received research grants and/or speaking fees from Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., AbbVie, Eisai Co., Ltd., MSD K.K., Bristol-Myers K.K., Takeda Pharmaceutical Co., Ltd. and Janssen Pharmaceutical K.K. Tadashi Okano received speaking fees from AbbVie. The other authors have no conflicts of interest to disclose. No specific funding was received from any companies in the public, commercial or not-for-profit sectors to carry out the work described in this article.
